MedCity News April 5, 2024
Frank Vinluan

Contineum Therapeutics plans to spend most of its IPO cash on clinical testing of a lead drug candidate in development for idiopathic pulmonary fibrosis and multiple sclerosis. This small molecule blocks a competitive target pursued by several other companies, including Bristol Myers Squibb and AbbVie.

Contineum Therapeutics, a biotech company developing drugs for applications in neurological disorders as well as immunology and inflammation indications, has raised $110 million in IPO cash to support a pipeline that includes a lead program in early clinical development for fibrosis.

San Diego-based Continuem needed to lower its expectations in order to proceed with the stock sale. In preliminary financial terms set earlier this week, the company aimed to offer 8.8 million shares for $16...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Clinical Trials, Investments, Partnerships, Pharma, Pharma / Biotech, Trends
Pharmacy Benefit Manager Reform Keeps Getting Scuttled, Despite Bipartisan Support
AI, patient data firms aim to speed up drug development
HHS files brief in 340B rebate model case: 4 takeaways
The Holy Grail of Biology
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients

Share This Article